Understanding blood in urine (hematuria) is crucial for accurate clinical documentation and medical coding. This resource provides information on diagnosing and documenting hematuria, including relevant ICD-10 codes, SNOMED CT concepts, and differential diagnoses for both gross hematuria and microscopic hematuria. Learn about common causes, symptoms, and diagnostic tests associated with blood in the urine to ensure proper patient care and accurate healthcare records.
Presence of red blood cells in the urine, visible or microscopic.
Pink, red, or brown urine; flank pain; painful urination; frequent urination.
Primary care, urgent care, nephrology, urology.
Complete code families applicable to R31.9
| Description | When to use |
|---|---|
| Blood in urine, visible or microscopic. | Use for any presence of blood in urine. Consider microscopic vs. gross hematuria. |
| Kidney stones obstructing urinary tract. | Use when imaging confirms kidney stones causing obstruction and hematuria. Code stone type. |
| Bladder infection causing bloody urine. | Use for hematuria associated with UTI symptoms and positive urine culture. |
Coding hematuria without specifying type (gross vs microscopic) or cause can lead to claim denials and inaccurate quality reporting. ICD-10 requires greater specificity.
Focusing solely on hematuria without coding the underlying condition (e.g., UTI, kidney stones) impacts reimbursement and clinical documentation integrity.
Incorrectly coding traumatic hematuria as a medical condition or vice-versa leads to inaccurate data reporting and potential compliance issues.
Confirm visible or microscopic hematuria (ICD-10 R31.x)
Review medication list for nephrotoxic drugs
Assess for urinary tract infection (UTI) symptoms
Consider recent trauma, exercise, or menstruation
Order urinalysis, urine culture, and imaging if indicated
Patient presents with hematuria, also documented as blood in urine. The onset, duration, and frequency of the hematuria were documented. Associated symptoms such as dysuria, urinary urgency, frequency, flank pain, abdominal pain, or fever were explored and documented. The patient's medical history, including prior episodes of hematuria, urinary tract infections, kidney stones, bladder cancer, prostate problems (in males), family history of kidney disease, recent trauma, use of anticoagulants, NSAIDs, or other medications known to cause hematuria, and relevant surgical history were reviewed. Physical examination findings, including vital signs, abdominal examination, costovertebral angle tenderness, and presence of edema, were noted. Differential diagnoses considered include urinary tract infection, nephrolithiasis, bladder cancer, kidney disease, trauma, medication-induced hematuria, and benign prostatic hyperplasia (in males). Preliminary diagnostic testing may include urinalysis with microscopic examination, urine culture, and potentially blood tests such as a complete blood count (CBC), basic metabolic panel (BMP), and coagulation studies. Further evaluation with imaging studies such as ultrasound, CT scan, or cystoscopy may be warranted depending on the initial findings and clinical suspicion. Treatment plan will be determined based on the underlying cause of the hematuria and may include antibiotics for infection, pain management, referral to urology for further evaluation and management of suspected urological conditions, or other interventions as clinically indicated. Patient education regarding potential causes, diagnostic workup, and treatment options for hematuria was provided. Follow-up care and monitoring were discussed and scheduled as appropriate.
Asymptomatic microscopic hematuria (AMH) in adults necessitates a thorough evaluation to rule out significant underlying pathology. Current guidelines, including those from the American Urological Association (AUA), recommend a staged approach. The initial workup typically involves a detailed history, physical examination, urinalysis with microscopy to confirm hematuria, and urine culture to exclude infection. Further investigation with renal function tests (serum creatinine, eGFR) is crucial. Depending on patient risk factors (age, smoking history, family history of urologic malignancy), imaging studies such as renal and bladder ultrasound, or CT urography may be warranted. Consider implementing a risk-stratified approach for AMH to optimize resource utilization and minimize unnecessary testing while ensuring timely detection of serious conditions. Explore how S10.AI can assist in streamlining this process by automating guideline adherence checks and generating personalized diagnostic pathways.
Differentiating between glomerular and non-glomerular hematuria requires integrating clinical, laboratory, and imaging findings. Glomerular hematuria typically presents with red blood cell casts and dysmorphic red blood cells on urine microscopy, often accompanied by proteinuria. Non-glomerular hematuria usually features isomorphic red blood cells without casts or significant proteinuria. Laboratory tests such as urine sediment analysis and assessment of renal function are essential. Imaging modalities like renal ultrasound can help identify structural abnormalities suggesting non-glomerular etiologies like kidney stones, tumors, or cysts. In cases where the distinction remains challenging, consider a nephrology consult for further evaluation, including a renal biopsy if indicated. Learn more about how S10.AI can facilitate differential diagnosis by correlating laboratory and imaging results with established diagnostic criteria for hematuria.
Cystoscopy is a crucial diagnostic tool in evaluating hematuria, especially in patients with risk factors for bladder cancer, including smoking history, occupational exposure to carcinogens, age over 50, and history of gross hematuria. AUA guidelines recommend cystoscopy for patients with microscopic hematuria and risk factors or persistent microscopic hematuria despite a negative initial workup. Pre-procedure considerations include informed consent, antibiotic prophylaxis if indicated, and appropriate pain management strategies. Post-procedure, patients should be monitored for complications such as urinary tract infection, bleeding, and urinary retention. Patient education regarding potential side effects and follow-up care is essential. Consider implementing standardized pre- and post-cystoscopy protocols to improve patient safety and outcomes. Explore how S10.AI can support clinical decision-making by integrating risk stratification tools for bladder cancer and providing evidence-based recommendations for cystoscopy referral.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.